

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|-------------|--|---|------------------------|
| APPLICANT: | ALLISON | } | EXAMINER: SNEDDEN, S. |
| SERIAL NO.: | 10/632,694 | | ART UNIT: 1653 |
| FILED: | AUGUST 1, 2003 | | CONFIRMATION NO.: 3876 |
| TITLE: | MODIFIED ANNEXIN PROTEINS AND METHODS FOR TREATING VASO-OCCLUSIVE SICKLE-CELL DISEASE | | |

Attention Certificate of Corrections Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**REQUEST FOR CERTIFICATE OF CORRECTION FOR
APPLICANT'S MISTAKE (37 CFR § 1.323)**

Sir:

Applicant notes that minor errors, described more fully below, occurred in good faith in the above-referenced application and correction of these mistakes do not involve such changes in the patent as would constitute new matter or would require reexamination. Issuance of a Certificate of Correction correcting these errors is requested.

Attached is Form PTO-1050, which is suitable for printing.

Column 1, line 45, should be corrected to read "infarction and consequent infection. Patients also suffer from".

Column 6, line 11, should be corrected to read "of sickle-cell disease. Splenic thrombosis often leads to".

Column 7, line 1, should be corrected to read "the inhibition of cellular amplification of platelet aggregation"; line 11 should be corrected to read "and increased safety (PCT International Publication No. WO)".

Column 12, line 35, should be corrected to read "annexin nucleic acid molecule. One embodiment is an iso-".

Column 20, line 35, should be corrected to read "ing vaso-occlusive crises, pain crises, Acute Chest Syndrome".

Column 24, line 15, should be corrected to read "annexin V binds to liposomes composed of 80% phosphati-".

Entry of this Certificate of Correction is respectfully requested.

Please send the Certificate to:

Customer No. 25871
Swanson & Bratschun, L.L.C.
8210 SouthPark Terrace
Littleton, Colorado 80120

Please charge any deficiency or credit any excess payment to deposit account No. 19-5117.

Respectfully submitted,



Date: October 23, 2007

Paul J. Prendergast, Reg. No. 46,068
Swanson & Bratschun, L.L.C.
8210 SouthPark Terrace
Littleton, Colorado 80120
Telephone: (303) 268-0066
Facsimile: (303) 268-0065

S:\CLIENTFOLDERS\ALAVITA (FORMERLY SURROMED)\113REQUEST TO CORRECT.DOC

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO. : 6,982,154

APPLICATION NO.: 10/632,694

ISSUE DATE : January 3, 2006

INVENTOR(S) : Anthony Allison

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 1, line 45, should be corrected to read "infarction and consequent infection. Patients also suffer from".

Column 6, line 11, should be corrected to read "of sickle-cell disease. Splenic thrombosis often leads to".

Column 7, line 1, should be corrected to read "the inhibition of cellular amplification of platelet aggregation"; line 11 should be corrected to read "and increased safety (PCT International Publication No. WO)".

Column 12, line 35, should be corrected to read "annexin nucleic acid molecule. One embodiment is an iso-".

Column 20, line 35, should be corrected to read "ing vaso-occlusive crises, pain crises, Acute Chest Syndrome".

Column 24, line 15, should be corrected to read "annexin V binds to liposomes composed of 80% phosphati-".

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Swanson & Bratschun, L.L.C.
8210 SouthPark Terrace
Littleton, Colorado 80120

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.